Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 Equity-to-Asset is 0.50 as of Feb. 2026, which is 4% above its 10-year median of 0.48. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.86 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 684 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 50% on this metric.
The historical rank and industry rank for COSMOS Pharmaceutical's Equity-to-Asset or its related term are showing as below:
CSMYF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41 Med: 0.48 Max: 0.53
Current: 0.48
During the past 13 years, the highest Equity to Asset Ratio of COSMOS Pharmaceutical was 0.53. The lowest was 0.41. And the median was 0.48.
CSMYF's Equity-to-Asset is ranked better than 50% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs CSMYF: 0.48
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
COSMOS Pharmaceutical Equity-to-Asset Related Terms
COSMOS Pharmaceutical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
COSMOS Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Equity-to-Asset of 0.50 as of Feb. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on COSMOS Pharmaceutical and its competitors. This is near median its historical median of 0.48. Over the past decade, COSMOS Pharmaceutical's Equity-to-Asset has ranged from 0.41 to 0.53. According to the industry distribution chart, COSMOS Pharmaceutical ranks #342 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 50%.
Is COSMOS Pharmaceutical's Equity-to-Asset too high?
COSMOS Pharmaceutical's current Equity-to-Asset of 0.50 is near median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 0.53. The Healthcare Providers & Services industry median Equity-to-Asset is 0.48. COSMOS Pharmaceutical's value of 0.50 is 4.2% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #342 out of 684 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Equity-to-Asset compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #342 out of 684 companies for Equity-to-Asset. This puts COSMOS Pharmaceutical in the upper half of its industry. The industry median Equity-to-Asset is 0.48. COSMOS Pharmaceutical's value of 0.50 is 4.2% above this benchmark. Historically, COSMOS Pharmaceutical's own Equity-to-Asset has ranged from 0.41 to 0.53 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 0.48, COSMOS Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Equity-to-Asset of 0.50 is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Equity-to-Asset is 0.50, which is near median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.86, compared to a current price of $37.06 — trading 28.5% below its estimated fair value. The current Equity-to-Asset is 0.50, which is near median its 10-year median of 0.48 and 4.2% above the Healthcare Providers & Services industry median of 0.48. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Equity-to-Asset is 0.50 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.5% below its estimated GF Value™ of $51.86.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Equity-to-Asset: 0.50 (near median its 10-year median of 0.48)
GF Value™: $51.86 vs. price of $37.06 (28.5% below fair value)
Industry Position: 4.2% above the Healthcare Providers & Services median (#342 of 684)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
